JP2011525169A - Ｔｏｌｌ様受容体３の選択的アゴニスト - Google Patents

Ｔｏｌｌ様受容体３の選択的アゴニスト Download PDF

Info

Publication number
JP2011525169A
JP2011525169A JP2010546793A JP2010546793A JP2011525169A JP 2011525169 A JP2011525169 A JP 2011525169A JP 2010546793 A JP2010546793 A JP 2010546793A JP 2010546793 A JP2010546793 A JP 2010546793A JP 2011525169 A JP2011525169 A JP 2011525169A
Authority
JP
Japan
Prior art keywords
poly
subject
cells
tlr3
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010546793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525169A5 (enExample
Inventor
カーター，ウィリアム・エイ
ストレイヤー，デーヴィッド
Original Assignee
へミスフェリックス・バイオファーマ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by へミスフェリックス・バイオファーマ，インコーポレーテッド filed Critical へミスフェリックス・バイオファーマ，インコーポレーテッド
Publication of JP2011525169A publication Critical patent/JP2011525169A/ja
Publication of JP2011525169A5 publication Critical patent/JP2011525169A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010546793A 2008-02-15 2009-02-17 Ｔｏｌｌ様受容体３の選択的アゴニスト Withdrawn JP2011525169A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2930708P 2008-02-15 2008-02-15
US61/029,307 2008-02-15
US5160608P 2008-05-08 2008-05-08
US61/051,606 2008-05-08
PCT/US2009/000959 WO2009102496A2 (en) 2008-02-15 2009-02-17 Selective agonist of toll-like receptor 3

Publications (2)

Publication Number Publication Date
JP2011525169A true JP2011525169A (ja) 2011-09-15
JP2011525169A5 JP2011525169A5 (enExample) 2012-05-17

Family

ID=40957440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546793A Withdrawn JP2011525169A (ja) 2008-02-15 2009-02-17 Ｔｏｌｌ様受容体３の選択的アゴニスト

Country Status (11)

Country Link
US (1) US20100310600A1 (enExample)
EP (1) EP2249845A4 (enExample)
JP (1) JP2011525169A (enExample)
KR (1) KR20100126390A (enExample)
CN (1) CN101990435A (enExample)
AU (1) AU2009215128A1 (enExample)
BR (1) BRPI0907515A2 (enExample)
CA (1) CA2715293A1 (enExample)
NZ (1) NZ587371A (enExample)
WO (1) WO2009102496A2 (enExample)
ZA (1) ZA201005826B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740011A1 (en) * 2008-10-10 2010-04-15 Hemispherx Biopharma, Inc. Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
WO2011072871A1 (en) * 2009-12-18 2011-06-23 Bavarian Nordic A/S Production of ifn-lambda by conventional dendritic cells and uses thereof
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
CN108498362A (zh) * 2018-04-17 2018-09-07 睿欧生物科技（上海）有限公司 预防及治疗口腔溃疡的Toll样受体激动剂漱口水
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN115487302A (zh) * 2022-11-09 2022-12-20 吉林大学 Toll样受体3在治疗华支睾吸虫性肝纤维化的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
US5063209A (en) * 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
ZA883887B (en) * 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5258369A (en) * 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
JP2010507361A (ja) * 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
AU2008223446B2 (en) * 2007-03-05 2012-02-02 Utah State University Restrictive agonist of Toll-like receptor 3 (TLR3)
AU2009215795A1 (en) * 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
CA2740011A1 (en) * 2008-10-10 2010-04-15 Hemispherx Biopharma, Inc. Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
US8722874B2 (en) * 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
WO2010104571A2 (en) * 2009-03-13 2010-09-16 Hemispherx Biopharma, Inc. Treating chronic fatigue syndrome and prolonged qt interval

Also Published As

Publication number Publication date
US20100310600A1 (en) 2010-12-09
EP2249845A2 (en) 2010-11-17
EP2249845A4 (en) 2012-02-29
WO2009102496A3 (en) 2009-11-05
CA2715293A1 (en) 2009-08-20
KR20100126390A (ko) 2010-12-01
WO2009102496A2 (en) 2009-08-20
AU2009215128A1 (en) 2009-08-20
BRPI0907515A2 (pt) 2015-07-28
CN101990435A (zh) 2011-03-23
ZA201005826B (en) 2011-10-26
NZ587371A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
Krieg Therapeutic potential of Toll-like receptor 9 activation
Wille-Reece et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses
Klinman Immunotherapeutic uses of CpG oligodeoxynucleotides
JP2011525169A (ja) Ｔｏｌｌ様受容体３の選択的アゴニスト
ES2872377T3 (es) Nanopartículas de protamina/ARN para inmunoestimulación
AU2008223446B2 (en) Restrictive agonist of Toll-like receptor 3 (TLR3)
US20170211068A1 (en) Immunostimulation by chemically modified rna
JP3976742B2 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
KR20160055863A (ko) 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도
EP2170931A1 (en) Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
JPWO2017007027A1 (ja) 免疫刺激オリゴヌクレオチド複合体
CA2632516C (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
Wang et al. Nanoparticles of Chitosan/Poly (D, L-Lactide-Co-Glycolide) enhanced the immune responses of haemonchus contortus HCA59 antigen in model mice
Tomai et al. TLR agonists as vaccine adjuvants
JP2020510052A (ja) 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用
KR102478043B1 (ko) 항원 전달용 조성물
Brown et al. Nucleic Acids as Adjuvants
Himes et al. 10 Clinical Development of Oligodeoxynucleotide TLR9 Agonists
Ronaghy ISS immune modulation, vaccination and the regulation of arthritis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130718